Europe
Clinical News
Informatics
Industry News
Practice Management
Education
Subspecialties
More
Sign In
CT
Digital X-Ray
Interventional
Molecular Imaging
MRI
Radiation Oncology/Therapy
Ultrasound
Womens Imaging
Molecular Imaging
PET/MRI reveals potential driver of migraine
By
Will Morton
Skull bone marrow TSPO-PET signal was positively associated with migraine frequency and was elevated compared with controls.
November 19, 2026
Lantheus presents phase III data for tau PET agent
By
AuntMinnie.com staff writers
The studies support the use of florquinitau F-18 for PET imaging of the brain.
November 17, 2026
Appropriate use criteria issued for FET-PET brain imaging
By
Will Morton
The workgroup rated FET PET as “appropriate” in two scenarios.
November 13, 2026
Clarity’s Cu-64 PSMA agent gets FDA breakthrough designation
By
AuntMinnie.com staff writers
The agent is indicated for PET imaging of PSMA-positive lesions in men with suspected prostate cancer recurrence.
November 12, 2026
SPECT-guided algorithm can aid in assessing Lu-177 RPT responses
By
Will Morton
Currently, there is no standardized approach for deciding when to continue or discontinue Lu-177 PSMA therapy after initial cycles.
November 12, 2026
SNMMI, QMIC partner on quantitative PET and SPECT standards
By
AuntMinnie.com staff writers
The collaboration aims to standardize quantitative PET and SPECT imaging in multicenter clinical trials and routine practice.
November 11, 2026
Actinium Pharmaceuticals launches HER3-targeted PET trial
By
AuntMinnie.com staff writers
The study will include patients with non-small cell lung cancer or with breast, colorectal, pancreatic, or ovarian cancer.
November 11, 2026
What are patients being told before, during, and after Lu-177 RPT?
By
Will Morton
The recommended duration for maintaining distance from others after treatment ranged from one to three days at some sites and up to seven days at others.
November 5, 2026
Lu-177 FAP-2286 controls lung cancer brain metastases
By
Will Morton
Brain metastasis from advanced lung cancer represents a formidable clinical challenge, primarily due to the protective blood brain barrier.
November 4, 2026
Radiopharm gets FDA nod on design of RAD101 phase III study
By
AuntMinnie.com staff writers
The FDA reviewed phase 2b data showing 93% concordance between MRI and RAD101 PET in patients with suspected recurrence.
November 4, 2026
Immuno-PET/CT detects myeloma missed by FDG-PET/CT
By
Will Morton
Standard FDG PET/CT misses active multiple myeloma in 30% to 50% of patients with biopsy-proven disease.
November 3, 2026
UW-Madison breaks ground on $62M cyclotron facility
By
AuntMinnie.com staff writers
The 13,000-square-foot facility, inside the existing Wisconsin Institutes for Medical Research complex, will house two new cyclotrons.
November 2, 2026
Page 1 of 638
Next Page